Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. https://meetinglibrary.asco.org/record/172411/abstract Promising new agent/trial for anyone with KRAS mutation. KRAS has previously...